Back to Awarded Treatment Trials
Awarded Trial: 02-STN-008-2
Grant ID
02-STN-008-2
Illness
Schizophrenia
Primary Drug/Intervention
Amoxapine
Primary Dosage
N/A
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Kapur
Sample Size
40
Duration of Study Period for Each Subject
N/A
Outcome Measurements
N/A
Results
Amoxapine is an off-patent antidepressant that is thought to have antipsychotic properties at certain doses. Forty patients with schizophrenia were randomized to receive amoxapine (up to 250 mg/day) or risperidone (up to 5mg/day) for 6 weeks. Thirty-nine patients completed the study. Amoxapine was equivalent to risperidone for positive, negative and depressive symptoms. Amoxapine produced fewer extrapyramidal side effects and less elevation of prolactin than risperidone. Amoxapine may be an attractive alternative to newer antipsychotics because it is very in expensive.
Publication
Apiquian R, Fresan A, Ulloa RE, de la Fuente-Sandoval C, Herrera-Estrella M, Vazquez A, Nicolini H, Kapur S. Amoxapine as an atypical antipsychotic: a comparative study vs. risperidone. Neuropsychopharmacology. 2005 Dec;30(12):2236-44.
Link
http://www.ncbi.nlm.nih.gov/pubmed/15956984
PI Name
Shitij Kapur
Degree
MD
Center
Centre for Addiction and Mental Health
Institution
Clarke Institute
Address
250 College Street
City or Town
Toronto
State or Province
Ontario
Zip or Postal Code
M5T 1RB
Country
Canada
Email Address
kapur@clarke-inst.on.ca